Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Patients Receiving Biological DMARDs (bDMARDs)

NCT05001672 is registered in ClinicalTrials.gov with Taipei Veterans General Hospital, Taiwan as lead sponsor.

NCT NCT05001672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05001672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Patients Receiving Biological DMARDs (bDMARDs)
Lead sponsor
Taipei Veterans General Hospital, Taiwan
Phase
Phase 4
Overall status
Unknown status
Start date
August 15, 2021
Completion date
December 31, 2025
Enrollment
108 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hbv, inflammatory arthritis